UNSPSC 51342304: Entecavir

This classification denotes an antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5968Y6H45M. European Medicines Agency schedules Entecavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21468. Entecavir generally arises in the molecular formula C12H15N5O3.H2O. The term ENTECAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule entecavir under HS 29335995 and SITC 51576.

As of Q4 2014, ENTECAVIR remains the US FDA Preferred Term for this commodity. Entecavir bears US NLM identifiers UMLS ID C0971023 and NCI Concept Code C65513. SMILES: C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N.

UNSPSC 51342304 Entecavir is a Commodity code that in recent state and local procurement activity encompasses a broader range of pharmaceutical procurement including naloxone, medical and first aid supplies, generic pharmaceuticals, and over-the-counter products — not entecavir specifically. State and local issuing bodies procuring under this code include county health departments, municipal fire departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Work being solicited ranges from emergency-response medical supplies for fire rescue divisions to generic pharmaceutical contracts distributed through authorized wholesalers to state and local facilities. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, and the City of Tampa issued an invitation to bid (26P00145) in March 2026 for 169 line items of medical and first aid supplies including respiratory equipment, cardiac monitoring electrodes, and medical consumables for the Tampa Fire Department Rescue Division, estimated at $700,000 and designated as a sheltered market opportunity exclusively for certified Small Local Business Enterprises with a 5 percent bid discount.

Recent procurement activity appears concentrated in Florida and the Upper Midwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, serving participating state and local government facilities across Minnesota and Oregon through three authorized wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as an information-gathering phase to explore direct-to-manufacturer prescription programs for self-insured employee group health plans and state agencies, preceding a formal RFP. The Tampa and Seminole County procurements reflect immediate supply needs; the MMCAP and Texas RFI represent longer-cycle, statewide or multi-state pharmaceutical frameworks.